PMID- 27926587
OWN - NLM
STAT- MEDLINE
DCOM- 20180223
LR  - 20220321
IS  - 1473-5636 (Electronic)
IS  - 0960-8931 (Linking)
VI  - 27
IP  - 2
DP  - 2017 Apr
TI  - Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab 
      immunotherapy: observational study of 39 patients.
PG  - 110-115
LID - 10.1097/CMR.0000000000000313 [doi]
AB  - In patients with ipilimumab (IPI)-refractory melanoma, the anti-programmed cell 
      death proteins 1 (PD1s) nivolumab (NIV) and pembrolizumab (PEM) are considered to 
      be a new standard of treatment. Few data are available on anti-PD1 safety in 
      patients who develop IPI-related severe adverse events (AEs) (grade>/=3). The aim 
      of this study was to compare the anti-PD1 safety and efficacy in patients with 
      previous severe toxicity to IPI versus in those showing moderate and no previous 
      IPI-related AEs. This single institution-based observational study included all 
      patients treated with anti-PD1 (PEM or NIV) and previously treated with IPI for 
      unresectable stage III or IV melanoma. The patients enrolled were classified 
      according to the occurrence of IPI-related AEs: group A: no previous IPI-related 
      AEs; group B: mild to moderate IPI-related AEs; and group C: severe to 
      life-threatening IPI-related AEs. The main outcome measure was safety of the 
      anti-PD1 among the three groups. The secondary endpoints included response 
      parameters. Groups A, B, and C included, respectively, 16, 13, and 10 patients. 
      The incidence of severe anti-PD1-related AEs (grades 3-4) was 12, 23, and 10% in 
      groups A, B, and C, respectively. One-year estimates of survival were 52.2, 73.4, 
      and 66.7% among the patients in groups A, B, and C, respectively. The number of 
      patients was too small to enable a meaningful statistical comparison. We did not 
      observe any difference in anti-PD1 toxicity onset incidence according to the 
      occurrence of previous IPI AEs. These reassuring real-life data should be 
      confirmed in a wider analysis.
FAU - Amode, Reyhan
AU  - Amode R
AD  - aDepartment of Dermatology, Saint-Louis Hospital bMelBase, Assistance publique 
      hopitaux de Paris cCRESS UMR 1153, Centre de recherche epidemiologie et 
      statistique Sorbonne Paris cite, Paris, France.
FAU - Baroudjian, Barouyr
AU  - Baroudjian B
FAU - Kowal, Anita
AU  - Kowal A
FAU - Jebali, Majdi
AU  - Jebali M
FAU - Allayous, Clara
AU  - Allayous C
FAU - Bagot, Martine
AU  - Bagot M
FAU - Madjlessi, Nika
AU  - Madjlessi N
FAU - Roux, Jennifer
AU  - Roux J
FAU - Viguier, Manuelle
AU  - Viguier M
FAU - Basset Seguin, Nicole
AU  - Basset Seguin N
FAU - Porcher, Raphael
AU  - Porcher R
FAU - Pages, Cecile
AU  - Pages C
FAU - Lebbe, Celeste
AU  - Lebbe C
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - England
TA  - Melanoma Res
JT  - Melanoma research
JID - 9109623
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents, Immunological)
RN  - 0 (Ipilimumab)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 31YO63LBSN (Nivolumab)
RN  - DPT0O3T46P (pembrolizumab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/*adverse effects/therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*adverse effects/therapeutic use
MH  - Antineoplastic Agents, Immunological/adverse effects/*therapeutic use
MH  - Disease-Free Survival
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunotherapy
MH  - Ipilimumab/*adverse effects
MH  - Male
MH  - Melanoma/*drug therapy/secondary
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Nivolumab
MH  - Programmed Cell Death 1 Receptor/*antagonists & inhibitors
MH  - Retreatment
MH  - Survival Rate
EDAT- 2016/12/08 06:00
MHDA- 2018/02/24 06:00
CRDT- 2016/12/08 06:00
PHST- 2016/12/08 06:00 [pubmed]
PHST- 2018/02/24 06:00 [medline]
PHST- 2016/12/08 06:00 [entrez]
AID - 10.1097/CMR.0000000000000313 [doi]
PST - ppublish
SO  - Melanoma Res. 2017 Apr;27(2):110-115. doi: 10.1097/CMR.0000000000000313.